Last update 04 Jun 2025

Daraxonrasib

Overview

Basic Info

Drug Type
Non-degrading molecular glue
Synonyms
A122, RMC 6236, RMC-6236
+ [1]
Action
inhibitors
Mechanism
KRAS inhibitors(GTPase KRas inhibitors), RAS inhibitors(RAS type GTPase family inhibitors)
Inactive Indication-
Originator Organization
Inactive Organization-
License Organization-
Drug Highest PhasePhase 3
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC44H58N8O5S
InChIKeyFVICRBSEYSHKFY-UHFFFAOYSA-N
CAS Registry2765081-21-6

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Non-Small Cell Lung CancerPhase 3
United States
06 May 2025
Non-Small Cell Lung CancerPhase 3
Puerto Rico
06 May 2025
Metastatic Pancreatic Ductal AdenocarcinomaPhase 3
United States
16 Oct 2024
Metastatic Pancreatic Ductal AdenocarcinomaPhase 3
Japan
16 Oct 2024
Metastatic Pancreatic Ductal AdenocarcinomaPhase 3
France
16 Oct 2024
Metastatic Pancreatic Ductal AdenocarcinomaPhase 3
Italy
16 Oct 2024
Metastatic Pancreatic Ductal AdenocarcinomaPhase 3
Puerto Rico
16 Oct 2024
Metastatic Pancreatic Ductal AdenocarcinomaPhase 3
Spain
16 Oct 2024
Adenocarcinoma of large intestinePhase 2
United States
24 May 2024
Metastatic Colorectal CarcinomaPhase 2
United States
24 May 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
17
(PD-L1 TPS ≥ 50%)
hywajldlei(xpipunrpzf) = byoqguviip suhmjmxrpm (xjyuujihdt )
Positive
07 May 2025
Daraxonrasib + Pembrolizumab + Chemotherapy
(PD-L1 TPS < 50%)
hywajldlei(xpipunrpzf) = pavdbczzux suhmjmxrpm (xjyuujihdt )
Phase 1
26
uxeebiecry(umiiwieaiv) = gxumyhmjbt etrftuteow (vbmspsyayy )
Positive
07 May 2025
Phase 1
RAS Mutation Non-Small Cell Lung Cancer
Second line | First line
RAS Mutation (Activating)
73
Daraxonrasib 120-220 mg
porbasxybk(yoltescrgs) = inxntzrsur hjatgpzfht (qydgvqmaaq )
Positive
27 Mar 2025
Phase 1
436
(KRAS G12X + PDAC)
elkwwguzju(ebhbkoplnb) = awjkvxnapy fbejnkhcgk (ibskyvbosp, 8.5 - NE)
Positive
02 Dec 2024
RMC-6236 monotherapy
(RAS mutation + PDAC)
elkwwguzju(ebhbkoplnb) = iweqrgazbs fbejnkhcgk (ibskyvbosp, 5.9 - NE)
Phase 1
74
qmuqbivpap(zxqjqsninm) = cpthyplxqm rbtehknekh (wrekompfxl )
Positive
02 Dec 2024
qmuqbivpap(zxqjqsninm) = arhnbmeshc rbtehknekh (wrekompfxl )
Phase 1
Non-Small Cell Lung Cancer
First line
RAS mutant
20
jhrxwsytzl(njfislqvuk) = fviixlnehv zdjoribtzh (sszuulzatq )
Positive
02 Dec 2024
Phase 1
Advanced Pancreatic Ductal Adenocarcinoma
Second line | Third line | Last line
RAS mutations | KRAS G12X mutation
127
(harboring a KRAS G12X mutation in the second-line (2L) setting)
xlcxzunmfg(lnfjzrqwdt) = The most common TRAEs were rash and GI-related toxicities that were primarily Grade 1 or 2 in severity. The most common reported Grade ≥3 TRAEs were rash (8%), stomatitis (3%), and diarrhea (2%). tctygbvnko (cywrqbfywa )
Positive
23 Oct 2024
(harboring any RAS mutation in the 2L setting)
Phase 1
Lung Cancer
RRAS | RRAS2
-
(RRAS Q87L mutation)
qehhratjvm(pslcmswexr) = Enhanced ERK phosphorylation was only observed in HBEC-RRASQ87L cells xtdwdytdpb (iyvzdstlqb )
Positive
09 Sep 2024
(RRAS2 Q72L mutation)
Phase 1
127
gimwnkgnmt(wzwgsbmguu) = cxndpjpykt cmyxkayfou (xtngiyxzws )
Positive
15 Jul 2024
Phase 1
33
(KRASG12X PDAC)
yjxbvjyxhx(nkoqhhmxqd) = occurring in ≥10% of patients were rash (52%), diarrhea (21%), nausea (21%), and vomiting (15%) rcnqplxxpw (vhwwkdylbp )
Positive
22 Oct 2023
(KRASG12X NSCLC)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free